Investors & Media

What's new.

Press releases

Press releases.

May 5th 2025

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

April 29th 2025

Immutep Quarterly Activities Report Q3 FY25

April 2nd 2025

Immutep to Participate in Upcoming Investor Conferences

more

Investor updates

Investor updates.

April 23rd 2025

Investor Update - April 2025

November 26th 2024

Investor Update - November 2024

February 21st 2024

Investor Update - February 2024

more

Analyst reports

Analyst reports.

May 6th 2025

Bell Potter - Strong Survival Data Supports Path Forward in Head & Neck; Buy (spec.), A$0.70/sh (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

Wilsons - 17.6m OS in PD-L1 negative mHNSCC; Maintain Overweight, A$1.05 PT (Analyst: Dr Shane Storey)

May 5th 2025

Baird - Encouraging Mature OS Data for Efti+Pembro in 1L HNSCC TPS<1; Rated OP, US$7 PT (Analyst: Colleen M. Kusy, CFA)

For a copy of this research report please contact your Baird advisor

more